Navigation Links
Patients Say MPM Medical's Regenecare Gel Significantly Reduced the Itching and Pain of Skin Rashes Triggered by Anti-Cancer Drugs
Date:3/30/2009

IRVING, Texas, March 30 /PRNewswire-FirstCall/ -- Patients undergoing cancer treatment reported that using Regenecare hydrogel significantly reduced the pain and itching associated with the sometimes-severe skin rashes caused by anti-cancer drugs.

Conducted by the Western University of Health Sciences, the study substantiated the findings of nine previous clinical trials recognizing Regenecare for its pain-relieving and wound-healing benefits. Manufactured by MPM Medical, Inc., Regenecare is the only wound and pain management product of its kind on the market.

"Pain management is one of the most-significant issues facing healthcare today," said MPM President Paul Miller. "Many patients stop or forgo treatment because they cannot tolerate the itching and painful side effects often associated with these treatments. Regenecare is a unique hydrogel whose benefits are substantiated by science and validated by patients."

The six-week study followed 13 patients who were taking a class of anti-cancer drugs that, while effective, often produce a severe rash on a patient's face, neck, back and legs. If scratched, these rashes can become infected. Patients reported "significant reduction" of itching when using Regenecare, according to the study.

Researchers credit Regenecare's unparalleled pain relief and wound healing to its formulation of 2% lidocaine (for local pain management), marine collagen (to promote tissue formation), Aloe vera (to enhance circulation and to promote emollient effect) and sodium alginate (to absorb exudates).

"Pain is the leading cause of disability in the United States and is straining our healthcare system," according to the National Pain Care Policy Act of 2008 (H.R. 2994). Among other things, the pending legislation seeks "to improve the assessment, understanding and treatment of pain."

MPM offers Regenecare HA as an over-the-counter version of the prescription Regenecare. Regenecare HA has the same formulation, but it also contains hyaluronic acid, which enhances moisture and healing. Consumers may purchase Regenecare and other MPM products online at www.MPMmedicalinc.com.

About RBC Life SciencesRBC Life Sciences (OTC Bulletin Board: RBCL) develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical, Inc., brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE RBC Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DaVitas IMPACT Program Reduces Mortality for New Dialysis Patients
2. Hormone Reduces Mortality in Heart Patients With High BP
3. LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination
4. Patients Bill of Rights Too Tough to Read
5. Emmi + KidsHealth = Prescription for Informed and Involved Patients
6. Individualized stroke treatment available for patients, though underutilized
7. External focus improves postural stability in patients with Parkinsons disease
8. Northeast Ohio's Center for Orthopedics Saves Patients Time with Online Next-Day Appointment Scheduling for its Open Cast Room
9. TMA Physicians and Legislators: Patients Have a Right to Know
10. Music Can Help Restore Stroke Patients Sight
11. Drug Combo Helps Larynx Cancer Patients Preserve Voice Box
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “God's Miracle ... Against All Odds” is the creation of published author, Keith C. A. Tucker, son ... the Christian Fellowship World Outreach pastured by Reverend Mark Hardy , “While sitting up ...
(Date:1/19/2017)... ... ... Next week after January 20th, the fear for many is that the humane ... of over 30 million. Many interviews with Dr. Carol Francis at the Los Angeles ... suppose to prioritize. Interviews provided below. , Among those present was Senator ...
(Date:1/19/2017)... ... 19, 2017 , ... This month, the CEO and Clinical Director of Sober ... rehab center in Delray Beach, Florida has been changed from Sober Living Outpatient to ... Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands of ...
(Date:1/19/2017)... ... January 19, 2017 , ... Remote Medical Technologies (RMT), ... transportable capabilities with their iMedHD2™ Portable Teleultrasound System. Compatible with ... that delivers HD, dynamic, streaming ultrasound images and video to one or more ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that it will be co-hosting a workshop entitled ... and drug delivery solutions to health industries worldwide. The one day event is ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Conference Call and Webcast to Follow Vanda Pharmaceuticals ... release results for the fourth quarter of 2016 on Wednesday, February ... ... 4:30 PM ET on Wednesday, February 15, 2017, during which management ... and other corporate activities. To participate in the conference call, please ...
(Date:1/19/2017)... BOSTON , Jan. 19, 2017  Stealth BioTherapeutics ... therapeutics to treat mitochondrial dysfunction, today announced new additions ... , M.D., as Chief Medical Officer, and Daniel ... Stealth announced that Jim Carr , Pharm.D. has ... "We are pleased to welcome Doug and Daniel ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  Abaxis, Inc. ... manufacturing point-of-care blood analysis instruments and consumables for the ... call to discuss its financial results for the third ... call will be at 4:15 p.m. ET on Thursday, ... for the third quarter fiscal year 2017 after the ...
Breaking Medicine Technology: